AdaptHealth Corp. (NASDAQ:AHCO) Shares Acquired by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC grew its stake in AdaptHealth Corp. (NASDAQ:AHCO) by 15.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,701,808 shares of the company’s stock after buying an additional 496,453 shares during the quarter. Segall Bryant & Hamill LLC owned 2.75% of AdaptHealth worth $41,571,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AHCO. Boston Partners acquired a new position in AdaptHealth in the 1st quarter worth about $693,000. Russell Investments Group Ltd. acquired a new position in AdaptHealth in the 1st quarter worth about $2,242,000. Royce & Associates LP raised its holdings in AdaptHealth by 13.5% in the 3rd quarter. Royce & Associates LP now owns 777,405 shares of the company’s stock worth $8,730,000 after purchasing an additional 92,740 shares during the period. Vanguard Group Inc. raised its holdings in AdaptHealth by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 10,017,722 shares of the company’s stock worth $115,304,000 after purchasing an additional 818,241 shares during the period. Finally, Harbor Capital Advisors Inc. raised its holdings in AdaptHealth by 142.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 449,840 shares of the company’s stock worth $5,052,000 after purchasing an additional 264,610 shares during the period. Institutional investors and hedge funds own 82.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Canaccord Genuity Group cut their price objective on AdaptHealth from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Robert W. Baird cut their price objective on AdaptHealth from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Truist Financial cut their price objective on AdaptHealth from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Royal Bank of Canada cut their price objective on AdaptHealth from $13.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, UBS Group cut their price objective on AdaptHealth from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, AdaptHealth currently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Insider Buying and Selling

In related news, Director David Solomon Williams III sold 4,000 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $11.26, for a total value of $45,040.00. Following the completion of the transaction, the director now directly owns 36,899 shares in the company, valued at approximately $415,482.74. This represents a 9.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Shaw Rietkerk sold 25,000 shares of the stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $11.24, for a total value of $281,000.00. Following the completion of the transaction, the chief operating officer now owns 212,611 shares of the company’s stock, valued at $2,389,747.64. The trade was a 10.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.43% of the stock is currently owned by company insiders.

AdaptHealth Price Performance

AHCO stock opened at $9.74 on Wednesday. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.24 and a quick ratio of 1.00. The business has a 50 day simple moving average of $10.56 and a 200-day simple moving average of $10.45. The firm has a market capitalization of $1.31 billion, a PE ratio of -5.90, a price-to-earnings-growth ratio of 1.34 and a beta of 1.11. AdaptHealth Corp. has a 1 year low of $6.43 and a 1 year high of $11.90.

AdaptHealth (NASDAQ:AHCO) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.02). The company had revenue of $805.90 million during the quarter, compared to analysts’ expectations of $809.32 million. AdaptHealth had a negative net margin of 6.57% and a positive return on equity of 9.62%. AdaptHealth’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the company earned $0.19 earnings per share. Equities research analysts anticipate that AdaptHealth Corp. will post 0.89 earnings per share for the current fiscal year.

AdaptHealth Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.